Table 2.
Patient risk scores
| Total | Starting daily dose | ||
|---|---|---|---|
| 60 mg | 30 mg | ||
| N = 11 107 | N = 3066 | N = 8041 | |
| CHADS2 score | |||
| Mean ± SD | 2.2 ± 1.3 | 1.8 ± 1.3 | 2.3 ± 1.4 |
| 0 | 993 (8.9) | 420 (13.7) | 573 (7.1) |
| 1 | 2777 (25.0) | 971 (31.7) | 1806 (22.5) |
| 2 | 3312 (29.8) | 881 (28.7) | 2431 (30.2) |
| 3 | 2203 (19.8) | 478 (15.6) | 1725 (21.5) |
| 4 | 1150 (10.4) | 230 (7.5) | 920 (11.4) |
| 5 | 516 (4.6) | 66 (2.2) | 450 (5.6) |
| 6 | 131 (1.2) | 14 (0.5) | 117 (1.5) |
| Unknown | 25 (0.2) | 6 (0.2) | 19 (0.2) |
| CHA2DS2‐VASc score | |||
| Mean ± SD | 3.5 ± 1.6 | 2.7 ± 1.5 | 3.8 ± 1.6 |
| 0 | 300 (2.7) | 206 (6.7) | 94 (1.2) |
| 1 | 941 (8.5) | 514 (16.8) | 427 (5.3) |
| 2 | 1861 (16.8) | 751 (24.5) | 1110 (13.8) |
| 3 | 2643 (23.8) | 745 (24.3) | 1898 (23.6) |
| 4 | 2453 (22.1) | 460 (15.0) | 1993 (24.8) |
| 5 | 1629 (14.7) | 262 (8.5) | 1367 (17.0) |
| 6 | 823 (7.4) | 92 (3.0) | 731 (9.1) |
| 7 | 341 (3.1) | 27 (0.9) | 314 (3.9) |
| 8 | 78 (0.7) | 3 (0.1) | 75 (0.9) |
| 9 | 13 (0.1) | 0 (0.0) | 13 (0.2) |
| Unknown | 25 (0.2) | 6 (0.2) | 19 (0.2) |
| HAS‐BLED Score a | |||
| Mean ± SD | 2.0 ± 1.0 | 1.7 ± 1.0 | 2.1 ± 0.9 |
| 0 | 570 (5.1) | 316 (10.3) | 254 (3.2) |
| 1 | 2610 (23.5) | 908 (29.6) | 1702 (21.2) |
| 2 | 4860 (43.8) | 1186 (38.7) | 3674 (45.7) |
| 3 | 2187 (19.7) | 478 (15.6) | 1709 (21.3) |
| 4 | 617 (5.6) | 119 (3.9) | 498 (6.2) |
| 5 | 53 (0.5) | 7 (0.2) | 46 (0.6) |
| 6 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 7 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unknown | 210 (1.9) | 52 (1.7) | 158 (2.0) |
Data are presented as number (%) unless otherwise indicated.
Abbreviation: SD, standard deviation.
a
Neither labile international normalized ratio nor alcohol use were counted; thus, the highest total score was seven.